Follow up of phenylketonuria patients

Molecular Genetics and Metabolism

Volumn 104, Issue SUPPL., 2011, Pages

  Demirkol, M ^a   Gizewska, M ^b   Giovannini, M ^c   Walter, J ^d  

^a ISTANBUL UNIVERSITY   (Turkey)

^b POMERANIAN MEDICAL UNIVERSITY   (Poland)

^c UNIVERSITY OF MILAN   (Italy)

^d MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Follow up; Management; Outcome; Phenylketonuria

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CYANOCOBALAMIN; DOPAMINE; MELANIN; NORADRENALIN; PHENYLALANINE; PYRIDOXINE; RETINOL; RIBOFLAVIN; SELENIUM; THYROXINE; TRACE ELEMENT; TYROSINE; UBIDECARENONE; VITAMIN D;

ATTENTION DEFICIT DISORDER; BLOOD SAMPLING; BODY WEIGHT; BONE MINERAL; BREAST FEEDING; COGNITION; DEPRESSION; DIET RESTRICTION; FAMILY; FOLLOW UP; GROWTH RETARDATION; HEALTH PROMOTION; HUMAN; NUTRITIONAL STATUS; OBESITY; PHENYLKETONURIA; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; VITAMIN DEFICIENCY;

FOLLOW-UP STUDIES; HUMANS; NUTRITIONAL STATUS; PHENYLKETONURIAS; PRACTICE GUIDELINES AS TOPIC; QUALITY ASSURANCE, HEALTH CARE; TREATMENT OUTCOME;

EID: 82755192932     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2011.08.005     Document Type: Review

References (115)

1. Walter J.H., White F.J., Hall S.K., MacDonald A., Rylance G., Boneh A., Francis D.E., Shortland G.J., Schmidt M., Vail A. How practical are recommendations for dietary control in phenylketonuria. Lancet 2002, 360:55-57.
2. Blau N., van Spronsen F.J., Levy H. Phenylketonuria. Lancet 2010, 376:1417-1427.
3. Feillet F., Agostoni C. Nutritional issues in treating phenylketonuria. J. Inherit. Metab. Dis. 2010, 33:659-664.
4. Mitchell J.J., Scriver C.R. Phenylalanine hydroxylase deficiency. GeneReviews [Internet] 1993, University of Washington, Seattle, Seattle (WA), [updated 2010 May]. R.A. Pagon, T.D. Bird, C.R. Dolan, K. Stephens (Eds.).
5. Simon E., Schwarz M., Roos J., Dragano N., Geraedts M., Siegrist J., Kamp G., Wendel U. Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria. Health Qual. Life Outcomes 2008, 6:25.
6. Antshel K.M. ADHD, learning, and academic performance in phenylketonuria. Mol. Genet. Metab. 2010, 99:S52-S58.
7. Brumm V.L., Bilder D., Waisbren S.E. Psychiatric symptoms and disorders in phenylketonuria. Mol. Genet. Metab. 2010, 99:S59-S63.
8. National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16-18, 2000. Pediatrics 2001, 108:972-982.
9. Burgard P., Bremer H.J., Bührdel P., Clemens P.C., Mönch E., Przyrembel H., Trefz F.K., Ullrich K. Rationale for the German recommendations for phenylalanine level control in phenylketonuria 1997. Eur. J. Pediatr. 1999, 158:46-54.
10. Report of Medical Research Council Working Party on Phenylketonuria: recommendations on the dietary management of phenylketonuria. Arch. Dis. Child. 1993, 68:426-427.
11. Ogier de Baulny H., Abadie V., Feillet F., De Parscau L. Managment of PKU and HPA. J. Nutr. 2007, 137:1561-1563.
12. Schweitzer-Krantz S., Burgard P. Survey of national guidelines for the treatment of phenylketonuria. Eur. J. Pediatr. 2000, 159:S70-S73.
13. Pietz J., Dunckelmann R., Rupp A., Rating D., Meinck H.M., Schmidt H., Bremer H.J. Neurological outcome in adult patients with early-treated phenylketonuria. Eur. J. Pediatr. 1998, 157:82-830.
14. Weglage J. Comments on behaviour in early treated phenylketonuria. Eur. J. Pediatr. 2000, 159:S94-S95.
15. van Spronsen F.J., Burgard P. The truth of treating patients with phenylketonuria after childhood. The need for a new guideline. J. Inherit. Metab. Dis. 2008, 31:673-679.
16. Levy H., Burton B., Cederbaum S., Scriver C. Recommendations for evaluation of responsiveness to tetrahydrobiopterin (BH(4)) in phenylketonuria and its use in treatment. Mol. Genet. Metab. 2007, 92:287-291.
17. Blau N., Bélanger-Quintana A., Demirkol M., Feillet F., Giovannini M., Trefz F.K., van Spronsen F.J. Optimizing the use of sapropterin (BH(4)) in the management of phenylketonuria. Mol. Genet. Metab. 2009, 96:158-163.
18. Blau N., Bélanger-Quintana A., Demirkol M., Feillet F., Giovannini M., MacDonald A., Trefz F.K., van Spronsen F.J. Management of phenylketonuria in Europe: Survey results from 19 centres. Mol. Genet. Metab. 2010, 99:109-115. contributing European PKU centres.
19. Ahring K., Bélanger-Quintana A., Dokoupil K., Gokmen-Ozel H., Lammardo A.M., MacDonald A., Motzfeld K., Nowacka M., Robert M., van Rijn M. Blood phenylalanine control in phenylketonuria: a survey of 10 European centres. Eur. J. Clin. Nutr. 2011, 65:275-278.
20. Koch R., Azen C., Friedman E.G., Fishler K., Baumann-Frischling C., Lin T. Care of adult with phenylketonuria. Eur. J. Pediatr. 1996, 155:S90-S92.
21. Smith I., Beasley M.G., Ades A.E. Intelligence and quality of dietary treatment in phenylketonuria. Arch. Dis. Child. 1990, 65:472-478.
22. Pardridge W.M. Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids. Neurochem. Res. 1998, 23:635-644.
23. Huijbregts S.C., de Sonneville L.M., Licht R., van Spronsen F.J., Verkerk P.H., Sergeant J.A. Sustained attention and inhibition of cognitive interference in treated phenylketonuria: association with concurrent and lifetime phenylalanine concentrations. Neuropsychologia 2002, 40:7-15.
24. MacDonald A., Rylance G., Hall S.K., Asplin D., Booth I.W. Factors affecting the variation in plasma phenylalanine in patients with phenylketonuria on diet. Arch. Dis. Child. 1996, 74:412-417.
25. MacDonald A., Rylance G.W., Asplin D., Hall S.K., Booth I.W. Does a single plasma phenylalanine predict quality of control in phenylketonuria. Arch. Dis. Child. 1998, 78:122-126.
26. Burton B.K., Leviton L. Reaching out to the lost generation of adults with early-treated phenylketonuria (PKU). Mol. Genet. Metab. 2010, 101:146-148.
27. Gassió R., Campistol J., Vilaseca M.A., Lambruschini N., Cambra F.J., Fuste E. Do adult patients with phenylketonuria improve their quality of life after introduction/resumption of a phenylalanine-restricted diet?. Acta Paediatr. 2003, 92:1474-1478.
28. Clarke J.T.R., Gates R.D., Hogan S.E., Barrett M., MacDonald G.W. Neuropsychological studies in adolescents with phenylketonuria returned to phenylalanine-restricted diets. Am. J. Ment. Retard. 1997, 92:255-262.
29. Brumm V.L., Azen C., Moats R.A., Stern A.M., Broomand C., Nelson M.D., Koch R. Neuropsychological outcome of subjects participating in the PKU adult collaborative study: a preliminary review. J. Inherit. Metab. Dis. 2004, 27:549-566.
30. Channon S., German E., Cassina C., Lee P. Executive functioning, memory, and learning in phenylketonuria. Neuropsychology 2004, 18:613-620.
31. Channon S., Mockler C., Lee P. Executive functioning and speed of processing in phenylketonuria. Neuropsychology 2005, 19:679-686.
32. Channon S., Goodman G., Zlotowitz S., Mockler C., Lee P.J. Effects of dietary management of phenylketonuria on long-term cognitive outcome. Arch. Dis. Child. 2007, 92:213-218.
33. Feldmann R., Denecke J., Grenzebach M., Weglage J. Frontal lobe-dependent functions in treated phenylketonuria: blood phenylalanine concentrations and long-term deficits in adolescents and young adults. J. Inherit. Metab. Dis. 2005, 28:445-455.
34. Leuzzi V., Rinalduzzi S., Chiarotti F., Garzia P., Trasimeni G., Accornero N. Subclinical visual impairment in phenylketonuria. A neurophysiological study (VEP-P) with clinical, biochemical, and neuroradiological (MRI) correlations. J. Inherit. Metab. Dis. 1998, 21:351-364.
35. Pietz J., Fatkenheuer B., Burgard P., Armbruster M., Esser G., Schmidt H. Psychiatric disorders in adult patients with early-treated phenylketonuria. Pediatrics 1997, 99:345-350.
36. Ris M., Weber A., Hunt M., Berry H., Williams S., Leslie N. Adult psychosocial outcome in early-treated phenylketonuria. J. Inherit. Metab. Dis. 1997, 20:499-508.
37. Schmidt H. Intelligence and professional career in young adults treated early for phenylketonuria. Eur. J. Pediatr. 1996, 155:S97-S100.
38. Cerone R., Schiaffino M.C., Di Stefano S., Veneselli E. Phenylketonuria: diet for life or not?. Acta Paediatr. 1999, 88:664-666.
39. Cleary M., Walter J.H. Assessment of adult phenylketonuria. Ann. Clin. Biochem. 2001, 38:450-458.
40. White D.A., Nortz M.J., Mandernach T., Huntington K., Steiner R.D. Deficits in memory strategy use related to prefrontal dysfunction during early development: evidence from children with phenylketonuria. Neuropsychology 2001, 15:221-229.
41. Anjema K., van Rijn M., Verkerk P.H., Burgerhof J.G., Heiner-Fokkema M.R., van Spronsen F.J. PKU: high plasma phenylalanine concentrations are associated with increased prevalence of mood swings. Mol. Genet. Metab. Jun. 2 2011, [Epub ahead of print].
42. Cabalska B., Duczyńska N., Borzymowska J., Zorska K., Kośłacz-Folga A., Bożkowa K. Termination of dietary treatment in phenylketonuria. Eur. J. Pediatr. 1977, 126:253-262.
43. Bik-Multanowski M., Didycz B., Mozrzymas R., Nowacka M., Kałużny L., Cichy W., Schneiberg B., Amilkiewicz J., Bilar A., Giżewska M., Lange A., Starostecka E., Chrobot A., Wójcicka-Bartłomiejczyk B.I., Milanowski A. Quality of life in non-compliant adults with phenylketonuria after resumption of the diet. J. Inherit. Metab. Dis. 2008, 265:630-633.
44. Koch R., Moseley M.D., Yano S., Nelson M., Moats R.A. Large neutral amino acid therapy and phenylketonuria: a promising approach to treatment. Mol. Genet. Metab. 2003, 79:110-113.
45. Matalon R., Michals-Matalon K., Bhatia G., Burlina A.B., Burlina A.P., Braga C., Fiori L., Giovannini M., Grechanina E., Novikov P., Grady J., Tyring S.K., Guttler F. Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine. J. Inherit. Metab. Dis. 2007, 30:153-158.
46. van Spronsen F.J., van Rijn M., van Dijk T., Smit G.P., Reijngoud D.J., Berger R., Heymans H.S. Plasma phenylalanine and tyrosine responses to different nutritional conditions (fasting/postprandial) in patients with phenylketonuria: effect of sample timing. Pediatrics 1993, 92:570-573.
47. Walter J.H., White F.J. Blood phenylalanine control in adolescents with phenylketonuria. Int. J. Adolesc. Med. Health 2004, 16:41-45.
48. Armstrong M.D., Stave U. A study of plasma free amino acid levels. II. Normal values for children and adults. Metabolism 1973, 22:561-569.
49. Ashley D.V., Barclay D.V., Chauffard F.A., Moennoz D., Leathwood P.D. Plasma amino acid responses in humans to evening meals of differing nutritional composition. Am. J. Clin. Nutr. 1982, 36:143-153.
50. Bickel H., Gerard J., Hickmans E.M. The influence of phenylalanine intake on the chemistry and behaviour of a phenylketonuric child. Acta Paediatr. 1954, 43:64-77.
51. Sharman R., Sullivan K.A., Young R.M., McGill J.J. Tyrosine monitoring in children with early and continuously treated phenylketonuria: results of an international practice survey. J. Inherit. Metab. Dis. Sep. 30 2010.
52. Posner J., Gorman D., Nagel B.J. Tyrosine supplements for ADHD symptoms with comorbid phenylketonuria. J. Neuropsychiatry Clin. Neurosci. 2009, 21:228-230.
53. Webster D., Wildgoose J. Tyrosine supplementation for phenylketonuria. Cochrane Database Syst. Rev. 2010, 8:CD001507.
54. Sharman R., Sullivan K., Young R., McGill J. A preliminary investigation of the role of the phenylalanine:tyrosine ratio in children with early and continuously treated phenylketonuria: toward identification of "safe" levels. Dev. Neuropsychol. 2010, 35:57-65.
55. Bick U., Farhendorf G., Ludolph A.G., Vasallo P., Weglage J., Ullrich K. Disturbed myelination in patients with treated hyperphenylalaninemias: evaluation with magnetic resonance imaging. Eur. J. Pediatr. 1991, 150:185-189.
56. Korinthenberg R., Ullrich K., Fullenkemper F. Evoked potentials and electroencephalography in adolescents with phenylketonuria. Neuropediatrics 1988, 19:175-178.
57. Schulpis K.H., Namopoulos C., Scarpalezou A., Bouloukos A., Missiou-Tsagarakis S. Serum carnitine level in phenylketonuria children under dietary control in Greece. Acta Paediatr. Scand. 1990, 79:930-934.
58. Lands W.E.M. Renewed questions about polyunsaturated fatty acid. Nutr. Rev. 1986, 44:189-195.
59. Agostini C., Verduci E., Fiori L., Riva E., Giovannini M. Breastfeeding rates among hyperphenylalaninemic infants. Acta Paediatr. 2000, 89:366-367.
60. WHO Infant and Young Child Feeding: Model Chapter for Textbooks for Medical Students and Allied health Professionals 2009, World Health Organization, Geneva.
61. Hüner G., Baykal T., Demir F., Demirkol M. Breastfeeding experience in inborn errors of metabolism other than phenylketonuria. J. Inherit. Metab. Dis. 2005, 28:457-465.
62. MacDonald A., Depont E., Evans S., Daly A., Hendriksz C., Charapani A.A., Saudubray J.M. Breastfeeding in IMD. J. Inherit. Metab. Dis. 2006, 29:299-303.
63. Riva E., Agostoni C., Biasucci G., Trojan S., Luotti D., Fiori L., Giovannini M. Early breastfeeding is linked to higher intelligence quotient score in dietary treated phenylketonuric children. Acta Paediatr. 1996, 85:56-58.
64. Raiha N.C.R. Milk protein quantity and quality and protein requirements during development. Adv. Pediatr. 1989, 36:347-348.
65. Horrocks L.A., Yeo Y.K. Health benefits of docosahexaenoic acid (DHA). Pharmacol. Res. 1999, 40:211-225.
66. Agostoni C., Harvie A., McCulloch D.L., Demellweek C., Cockburn F., Giovannini M., Murray G., Harkness R.A., Riva E. A randomised trial of long-chain polyunsaturated fatty acid supplementation in infants with phenylketonuria. Dev. Med. Child Neurol. 2006, 48:207-212.
67. Gokmen-Ozel H., MacDonald A., Daly A., Hall K., Ryder L., Chakrapani A. Long-term efficacy of 'ready-to-drink' protein substitute in phenylketonuria. J. Hum. Nutr. Diet. 2009, 22:422-427.
68. Vugteveen I., Hoeksma M., Monsen A.L., Fokkema M.R., Reijngoud D.J., van Rijn M., van Spronsen F.J. Serum vitamin B12 concentrations within reference values do not exclude functional vitamin B12 deficiency in PKU patients of various ages. Mol. Genet. Metab. 2011, 102:13-17.
69. Koletzko B., Lien E., Agostoni C., Böhles H., Campoy C., Cetin I., Desci T., Dudenhausen J.W., Dupont C., Forsyth S., Hoesli I., Holzgreve W., Lapillonne A., Putet G., Secher N.J., Symonds M., Szajewska H., Willatts P., Uauy R. World Association of Perinatal Medicine Dietary Guidelines Working Group, the roles of long-chain polyunsaturated fatty acids in pregnancy, lactation and infancy: review of current knowledge and consensus recommendations. J. Perinat. Med. 2008, 36:5-14.
70. Yi S.H., Kable J.A., Evatt M.L., Singh R.H. A cross-sectional study of docosahexaenoic acid status and cognitive outcomes in females of reproductive age with phenylketonuria. J. Inherit. Metab. Dis. 2011, 34:455-463.
71. Agostoni C., Verduci E., Massetto N., Fiori L., Radaelli G., Riva E., Giovannini M. Long term effects of long-chain polyunsaturated fats in hyperphenylalaninemic children. Arch. Dis. Child. 2003, 88:582-583.
72. Koletzko B., Beblo S., Demmelmair H., Müller-Felber W., Hanebutt F.L. Does dietary DHA improve neural function in children? Observations in phenylketonuria. Prostaglandins Leukot. Essent. Fatty Acids 2009, 81:159-164.
73. Koletzko B., Beblo S., Demmelmair H., Hanebutt F.L. Omega-3 LC-PUFA supply and neurological outcomes in children with phenylketonuria (PKU). J. Pediatr. Gastroenterol. Nutr. 2009, 48:S2-S7.
74. Vilaseca M.A., Lambruschini N., Gómez-López L., Gutiérrez A., Moreno J., Tondo M., Artuch R., Campistol J. Long-chain polyunsaturated fatty acid status in phenylketonuric patients treated with tetrahydrobiopterin. Clin. Biochem. 2010, 43:411-415.
75. van der Schot L.W., Doesburg W.H., Sengers R.C. The phenylalanine response curve in relation to growth and mental development in the first years of life. Acta Paediatr. 1994, 407:S68-S69.
76. Verkerk P.H., van Spronsen F.J., Smit G.P., Sengers R.C. Impaired prenatal and postnatal growth in Dutch patients with phenylketonuria, The National PKU Steering Committee. Arch. Dis. Child. 1994, 71:114-118.
77. van Spronsen F.J., Verkerk P.H., van Houten M. Does impaired growth of PKU patients correlate with the strictness of dietary treatment? National Dutch PKU Steering Committee. Acta Paediatr. 1997, 86:816-818.
78. Acosta P.B., Yannicelli S., Singh R., Mofidi S., Steiner R., DeVincentis E., Jurecki E., Bernstein L., Gleason S., Chetty M., Rourse B. Nutrient intakes and physical growth of children with phenylketonuria undergoing nutrition therapy. J. Am. Diet. Assoc. 2003, 103:1167-1173.
79. McBurnie M.A., Kronmal R.A., Koch R., Azen C.G. Physical growth of children treated for phenylketonuria. Ann. Hum. Biol. 1991, 18:357-368.
80. Scaglioni S., Verduci E., Fiori L., Lammardo A.M., Rossi S., Radaelli G., Riva E., Giovannini M. Body mass index rebound and overweight at 8 years of age in hyperphenylalaninemic children. Acta Paediatr. 2004, 93:1596-1600.
81. van Spronsen F.J., Ahring K., Giżewska M. PKU - what is daily practice in various centres in europe?. J. Inherit. Metab. Dis. 2009, 32:58-64.
82. Güttler F. Hyperphenylalaninemia: diagnosis and classification of the various types of phenylalanine hydroxylase deficiency in childhood. Acta Paediatr. Scand. 1980, 280:1-80.
83. Ponzone A., Mussa A., Porta F. In response to F.J. van Spronsen et al., Phenylalanine tolerance can already reliably be assessed at the age of 2 years in patients with PKU. J. Inherit. Metab. Dis. 2009, 32:584-586.
84. Adamczyk P., Morawiec-Knysak A., Płudowski P., Banaszak B., Karpe J., Pluskiewicz W. Bone mineral and the muscle-bone relationship in children, adolescents and young adults with phenylketonuria. J. Bone Miner. Metab. August 13 2010, Published online. 10.1007/s00774-010-0216-x.
85. Greeves L.G., Carson D.J., Magee A., Patterson C.C. Fractures and phenylketonuria. Acta Paediatr. 1997, 86:242-244.
86. Zeman J., Bayer M., Štépán J. Bone mineral density in patients with phenylketonuria. Acta Paediatr. 1999, 88:1348-1351.
87. Perez-Duenas B., Cambra F.J., Vilaseca M.A., Lambruschini N., Campistol J., Camacho J.A. New approach to osteopenia in phenylketonuric patients. Acta Paediatr. 2002, 99:899-904.
88. Modan-Moses D., Vered I., Schwartz G., Anikster Y., Abraham S., Segev R., Efrati O. Peak bone mass in patients with phenylketonuria. J. Inherit. Metab. Dis. 2007, 30:202-208.
89. McMurry M.P., Chan G.M., Leonard C.O., Ernst S.L. Related bone mineral status in children with phenylketonuria-relationship to nutritional intake and phenylalanine control. Am. J. Clin. Nutr. 1992, 55:997-1004.
90. Barat P., Barthe N., Redonnet-Vernhet I., Parrot F. The impact of the control of serum phenylalanine levels on osteopenia in patients with phenylketonuria. Eur. J. Paediatr. 2002, 161:687-688.
91. Yannicelli S., Medeiros D.M. Elevated plasma phenylalanine concentrations may adversely affect bone status of phenylketonuric mouse. J. Inherit. Metab. Dis. 2002, 25:347-361.
92. Watkins B.A., Yong L., Lippman H.E., Feng S. Modulatory effect of omega-3 polyunsaturated fatty acids on osteoblast function and bone metabolism. Prostaglandins Leukot. Essent. Fatty Acids 2003, 68:387-398.
93. Lage S., Bueno M., Andrate F., Prieto J.A., Delgado C., Legarda M., Sanjurjo P., Aldámiz-Echevarria L.J. Fatty acid profile in patients with phenylketonuria and its relationship with bone mineral density. J. Inherit. Metab. Dis. Sept. 10 2010, [Epub ahead of print].
94. Cleary M.A., Walter J.H., Wraith J.E., Jenkins J.P., Alani S.M., Tyler K., Whittle D. Magnetic resonance imaging of the brain in phenylketonuria. Lancet 1994, 344:87-90.
95. Anderson PJ P.J., Leuzzi V. White matter pathology in phenylketonuria. Mol. Genet. Metab. 2010, 99:S3-S9.
96. Moller H.E., Ullrich K., Weglage J. In vivo proton magnetic resonance spectroscopy in phenylketonuria. Eur. J. Pediatr. 2000, 159:S121-S125.
97. Albrecht J., Garbade S.F., Burgard P. Neuropsychological speed tests and blood phenylalanine levels in patients with phenylketonuria: a meta-analysis. Neurosci. Biobehav. Rev. 2009, 33:414-421.
98. Dawson C., Murphy E., Maritz C., Chan H., Ellerton C., Carpenter R.H., Lachmann R.H. Dietary treatment of phenylketonuria: the effect of phenylalanine on reaction time. J. Inherit. Metab. Dis. 2011, 34:449-454.
99. Gentile J.K., Ten Hoedt A.E., Bosch A.M. Psychosocial aspects of PKU: hidden disabilities-a review. Mol. Genet. Metab. 2010, 99:S64-S67.
100. Feillet F., MacDonald A., Hartung (Perron) D., Burton B. Outcomes beyond phenylalanine: an international perspective. Mol. Genet. Metab. 2010, 99:S79-S85.
101. Camfield C.S., Joseph M., Hurley T., Campbell K., Sanderson S., Camfield P.R. Optimal management of phenylketonuria: a centralized expert team is more successful than a decentralized model of care. J. Pediatr. 2004, 145:53-57.
102. Olsson G.M., Montgomery S.M., Alm J. Family conditions and dietary control in phenylketonuria. J. Inherit. Metab. Dis. 2007, 30:708-715.
103. Weglage J., Funders B., Wilken B., Schubert D., Schmidt E., Burgard P., Ullrich K. Psychological and social findings in adolescents with phenylketonuria. Eur. J. Pediatr. 1992, 151:522-525.
104. Moyle J.J., Fox A.M., Arthur M., Bynevelt M., Burnett J.R. Meta-analysis of neuropsychological symptoms of adolescents and adults with PKU. Neuropsychol. Rev. 2007, 17:91-101.
105. Szybowska M., Hewson S., Antle B.J., Babul-Hirji R. Assessing the informational needs of adolescents with a genetic condition: what do they want to know?. J. Genet. Couns. 2007, 16:201-210.
106. Dale J., Caramlau I.O., Lindenmeyer A., Williams S.M. Peer support telephone calls for improving health. Cochrane Database Syst. Rev. 2008, CD006903.
107. MacDonald A., Davies P., Daly A., Hopkins V., Hall S.K., Asplin D., Hendriksz C., Chakrapani A. Does maternal knowledge and parent education affect blood phenylalanine control in phenylketonuria?. J. Hum. Nutr. Diet. 2008, 21:351-358.
108. MacDonald A., Carver S., Daly A., Hopkins V., Hendriksz C., Vijay S., Chakrapani A. Service improvements with PKU clinic. J. Inherit. Metab. Dis. 2008, 31:145.
109. MacDonald A., Manji N., Evans S., Davies P., Daly A., Hendriksz C., Chakrapani A. Home delivery of dietary products in inherited metabolic disorders reduces prescription and dispensing errors. J. Hum. Nutr. Diet. 2006, 19:375-381.
110. MacDonald A., Gokmen-Ozel H., van Rijn M., Burgard P. The reality of dietary compliance in the management of phenylketonuria. J. Inherit. Metab. Dis. 2010, 33:665-670.
111. Cabana M.D., Rand C.S., Powe N.R., Wu A.W., Wilson M.H., Abboud P.A., Rubin H.R. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999, 282:1458-1465.
112. Feillet F., van Spronsen F.J., MacDonald A., Trefz F.K., Demirkol M., Giovannini M., Bélanger-Quintana A., Blau N. Challenges and pitfalls in the management of phenylketonuria. Pediatrics 2010, 126:333-341.
113. The Royal College of Physicians of Edinburgh Think transition. Developing the Essential link Between Paediatric and Adult care 2008.
114. Department of Health UK Transition: Moving on Well 2008.
115. Mütze U., Roth A., Weigel J.F., Beblo S., Baerwald C.G., Bührdel P., Kiess W. Transition of young adults with phenylketonuria from pediatric to adult care. J. Inherit. Metab. Dis. 2011, 34:701-709.